Linlin Wang

Cancer Hospital of Shangdong First Medical University

Disclosures:

  • Employment: none
  • Compensation: none
  • Ownership: none
  • Leadership: none

Presentations

Sep 28

180 - Firmonertinib plus Radiotherapy vs. Concurrent Chemoradiotherapy followed by Firmonertinib Consolidation in Unresectable Stage III <em>EGFR</em>-mutant NSCLC: A Randomized Phase 2 Trial
11:15am - 11:25am ET